Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on AngioDynamics (NASDAQ:ANGO) but lowers the price target from $18 to $13.
July 17, 2024 | 7:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on AngioDynamics but lowers the price target from $18 to $13.
The maintained Buy rating suggests continued confidence in AngioDynamics' long-term prospects. However, the lowered price target indicates potential short-term challenges or adjustments in valuation expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100